Tag: Sun Pharma

Sun Pharma has launched FluGuard® (Favipiravir 200 mg) at a comparatively economical price of Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India...............

The drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle everyday with the chronic nature of plaque psoriasis..........................

Sun Pharma and Hikma have entered into an exclusive licensing agreement for ILUMYA for the Middle East and North Africa regions...................

Clinical trial of the drug that has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with ICGEB will be conducted across 12 centers in India in 210 patients; results expected by October 2020.............................

The two companies have announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders.............

As per the terms of the agreement, Sun Pharma will be responsible for development, regulatory filings and manufacturing the products covered in the agreement while AstraZeneca will exclusively promote and distribute these products in China...................

Sun Pharma and China Medical System Holdings have entered into licensing agreement for generic products in Mainland China..............

Sun Pharma gets an exclusive global license for CSIR-IICT’s patents related to certain compounds with potential therapeutic activity across multiple indications. CSIR-IICT to get upfront plus milestone payments and royalties on net sales...................

Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development..................

The phytopharmaceuticals are being developed for treating individuals infected with Zika virus and possibly for curing Zika disease......